Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MMED files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMiniMed replaces director Brett Wall with Medtronic executive Scott Cundy
Filed May 18, 2026 · Period ending May 17, 2026 · ~1 min read
Key Changes
-
low
Brett Wall resigns from Board effective July 3, 2026, following his departure from parent company Medtronic; resignation not due to any disagreement with management or Board.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
Scott Cundy, Medtronic's SVP and Chief Quality, Development, and Innovation Officer, appointed to fill vacancy as class II director effective July 3, 2026.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
Cundy will join the Nominating and Corporate Governance Committee and serve through the 2027 annual meeting.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
MiniMed disclosed a routine board transition tied to personnel changes at its parent company Medtronic. Brett Wall, who serves as a class II director and member of the Nominating and Corporate Governance Committee, will resign effective July 3, 2026, following his departure as Executive Vice President and President of Medtronic's Neuroscience Portfolio.
The filing explicitly states his resignation is not due to any disagreement with management or the Board. Scott Cundy will replace Wall on the same effective date. Cundy currently serves as Medtronic's Senior Vice President and Chief Quality, Development, and Innovation Officer, leading global quality, product development, and innovation functions.
He is a member of Medtronic's Executive Committee and oversees the company's Engineering and Innovation Center. This represents a standard succession within the parent company's governance structure, maintaining continuity in board composition and committee membership.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) and member of the Board’s Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026. His decision to resign is not the result of any disagreement with management or the Board related to MiniMed’s operations, policies, or practices. His decision to resign results from his departure as Executive Vice President and President, Neuroscience Portfolio, of Medtronic plc (“Medtronic”), the parent company of MiniMed, which nominated Mr. Wall as a member of the Board.
Brett Wall, a class II director and member of the Nominating and Corporate Governance Committee, will resign from the Board effective July 3, 2026. The resignation is tied to his departure from Medtronic, MiniMed's parent company, which originally nominated him to the Board. The filing explicitly states his decision is not due to any disagreement with management or the Board regarding operations, policies, or practices.
Added in current filing · verify on EDGAR →
On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall’s departure. Mr. Cundy will serve as class II director whose term expires at the 2027 annual meeting of stockholders and will be a member of the Board’s Nominating and Corporate Governance Committee.
Scott Cundy was appointed to the Board effective July 3, 2026, filling the vacancy left by Brett Wall's resignation. He will serve as a class II director with a term expiring at the 2027 annual meeting and will join the Nominating and Corporate Governance Committee. This represents a routine board succession within the parent company's governance structure.
Added in current filing · verify on EDGAR →
Mr. Cundy currently serves as Senior Vice President and Chief Quality, Development, and Innovation Officer at Medtronic, leads the Global Quality, Product Development, and Innovation functions at Medtronic and is a member of the Medtronic Executive Committee. Mr. Cundy also oversees the Medtronic Engineering and Innovation Center. Prior to joining Medtronic in 2023, Mr. Cundy served as Vice President Quality, Regulatory, & Clinical Affairs Diagnostics and Life Sciences Platforms at Danaher Corporation.
Scott Cundy brings senior leadership experience from Medtronic, where he serves as SVP and Chief Quality, Development, and Innovation Officer, leading global quality, product development, and innovation functions. He is a member of Medtronic's Executive Committee and oversees the Engineering and Innovation Center. Before joining Medtronic in 2023, he held a quality and regulatory leadership role at Danaher Corporation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 8, 2026 · How we verify